# A Study of the Efficacy, Safety and Tolerability Profile of CSL Limited's Influenza Virus Vaccine (CSL's IVV) Administered Intramuscularly in Healthy Adults

> **NCT00562484** · PHASE4 · COMPLETED · sponsor: **Seqirus** · enrollment: 7500 (actual)

## Conditions studied

- Influenza

## Interventions

- **BIOLOGICAL:** CSL Limited Influenza Vaccine
- **BIOLOGICAL:** Placebo

## Key facts

- **NCT ID:** NCT00562484
- **Lead sponsor:** Seqirus
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-03
- **Primary completion:** 2009-11
- **Final completion:** 2010-01
- **Target enrollment:** 7500 (ACTUAL)
- **Last updated:** 2017-11-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00562484

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00562484, "A Study of the Efficacy, Safety and Tolerability Profile of CSL Limited's Influenza Virus Vaccine (CSL's IVV) Administered Intramuscularly in Healthy Adults". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00562484. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*